Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds. Joint technical showcase presentation at Informex, Charlotte, NC, USA, Feb 7, Booth: 1987
Joint project will offer a cost-effective, environmentally friendly process to produce betaine, an animal feed ingredient in short supply.
Novasep’s role in scaling up this patented process helped Nutritis close a EUR 13.5M financing round and acquire a fructose unit exclusively for fruit processing.
Electrodialysis and manufacturing process companies come together to design the most cost-effective whey demineralization solutions offering guaranteed performance.
Novasep appoints a new Chairman for its Supervisory Board Bernard Dubois, former Aventis Senior VP of Global Industrial Operations brings a wealth of experience to Novasep’s top management team.
July 26, 2010 - Toulouse and Pompey, France: Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce today that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.
Combination of instrAction and Novasep know-how sets a new standard for small molecule purification processes for the life science industries.
Stephen Stefano heads up Novasep North American business and PatrickGlaser leads Novasep Synthesis division.
Provepharm’s methylthioninium chloride “Proveblue®” dramatically decreases risk posed by dangerous impurities in methylene blue and opens way for use in applications including methemoglobinemia, urinary infections and malaria.